Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D pz-cel (prademagene zamikeracel) BLA submitted for investigational autologous, COL7A1 gene-corrected epidermal sheets for RDEB. Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Dec 2, 2024 Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Press Release Nov 14, 2024 Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates View Press Release Nov 12, 2024 Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
